Supernus Pharmaceuticals Prepares for CNS Therapeutics Conference
ROCKVILLE, Md. — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a key player in the biopharmaceutical industry, specializes in developing innovative treatments for central nervous system (CNS) diseases. Recently, the company announced an important upcoming appearance at the Bank of America Securities 2025 CNS Therapeutics Virtual Conference, where Jack A. Khattar, President and CEO, is scheduled to give a presentation on December 8, 2025, at 3:20 p.m. ET.
Engagement with Investors
Supernus Pharmaceuticals is keen to engage with interested investors during this conference. Those wishing to connect with company leadership are encouraged to reach out to the conference coordinator at Bank of America for potential meeting arrangements. Furthermore, a live audio webcast of the presentation will be available for participants who wish to follow along remotely. Please check the Supernus Pharmaceuticals Investor Relations website to access the presentation and other relevant materials.
Accessing the Live Webcast
The live audio webcast featuring Jack A. Khattar’s presentation will be available through the Supernus Pharmaceuticals Investor Relations portal. An archived version of this webcast will also be accessible for 60 days following the conclusion of the conference, ensuring that those who cannot attend live can still gain insight into the company’s latest developments.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is dedicated to the development and commercialization of products aimed at treating CNS diseases. Their extensive portfolio includes established treatments for various conditions, including attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease patients using levodopa-based therapies, hypomobility in Parkinsonian patients, postpartum depression, epilepsy, migraine, and chronic sialorrhea. Moreover, the company is actively advancing a range of novel product candidates targeting various CNS disorders.
Diverse Portfolio and Innovation
The commitment of Supernus Pharmaceuticals to innovation in neuroscience reflects in their comprehensive pipeline aimed at producing effective interventions for patients with CNS conditions. The company's research and development efforts are grounded in understanding patient needs and developing therapies that can improve their quality of life.
Continued Commitment to Excellence
Supernus Pharmaceuticals remains focused on pursuing excellence in the biopharmaceutical sector. Their commitment extends beyond product development; the company actively seeks to enhance its manufacturing capabilities, establish collaborations for research and development, and navigate the regulatory landscape efficiently. By doing so, they aim to ensure that groundbreaking treatments arrive in the hands of those who need them the most.
Stay Informed
For ongoing updates and further information on their product pipelines, clinical trials, and corporate strategies, follow Supernus Pharmaceuticals through their Investor Relations website. This transparency allows stakeholders and the public to stay informed about important developments and strategies intended to drive the company forward.
Frequently Asked Questions
What is the purpose of the upcoming conference?
The conference serves as a platform for Supernus Pharmaceuticals to present its advancements in CNS treatments and engage with investors and stakeholders.
How can investors connect with Supernus Pharmaceuticals during the event?
Investors can reach out to the Bank of America conference coordinator to schedule meetings with company management.
What types of conditions does Supernus Pharmaceuticals focus on?
They focus on various CNS diseases, including ADHD, Parkinson's disease, epilepsy, migraines, and more.
Will the presentation be accessible after the live event?
Yes, a replay of the presentation will be available on the Supernus Pharmaceuticals website for 60 days after the conference.
How does Supernus Pharmaceuticals support innovation?
Supernus fosters innovation through extensive research, collaboration, and an unwavering commitment to developing effective treatments for CNS disorders.